Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.34 |
| ▸ | CDC42BPB | Q9Y5S2 | 5/20 | 0.34 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18602494 | 0.97 | ROCK2 (0.33) | ROCK2ROCK1CDC42BPBCDC42BPASOS1 | |
| SCHEMBL19121494 | 0.95 | ROCK2 (0.34) | ROCK2ROCK1CDC42BPBCDC42BPASOS1 | |
| SCHEMBL19120916 | 0.90 | — | — | |
| SCHEMBL19121218 | 0.90 | ROCK2 (0.32) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL17813254 | 0.87 | SOS1 (0.31) | SOS1SOS2 | |
| SCHEMBL23602727 | 0.84 | ROCK2 (0.31) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL18820459 | 0.84 | ROCK2 (0.33) | ROCK2ROCK1CDC42BPBCDC42BPASOS1 | |
| SCHEMBL24221051 | 0.84 | — | — | |
| SCHEMBL24923748 | 0.81 | CHRM2 (0.34) | — | |
| SCHEMBL18820464 | 0.81 | ROCK2 (0.34) | ROCK2ROCK1CDC42BPBCDC42BPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280175-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | ROCK2 1262/4885ROCK1 516/4885CDC42BPB 1011/4885 |
| US-10280175-B2 | Hepatitis B antiviral agents | ZC3HAV1, HAVCR2, SLC10A1 | ROCK2 1284/4885ROCK1 484/4885CDC42BPB 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.